ACE-031 is a recombinant fusion protein joining the extracellular domain of the human activin receptor type IIB to the Fc region of human immunoglobulin G1. It works as a decoy receptor, binding myostatin, activin A and related TGF-beta family ligands in solution before they can reach receptors on the cell surface. It is the receptor-side counterpart to follistatin, which traps the same ligands using a natural binding protein.
Key facts
| Type | Soluble activin receptor type IIB and immunoglobulin Fc fusion protein |
| Architecture | ActRIIB extracellular domain joined to a human IgG1 Fc hinge and constant region |
| Quaternary structure | Disulfide-linked homodimer, giving two ligand binding sites |
| Approximate mass | Around 110 kDa for the glycosylated dimer |
| Principal ligands | Myostatin, activin A, activin B, GDF-11, BMP-9 and BMP-10 |
| Expression system | Mammalian cell culture, typically Chinese hamster ovary cells |
| Comparator molecules | Follistatin, ActRIIA-Fc constructs, anti-myostatin antibodies |
| Synonyms | ActRIIB-Fc, soluble activin receptor IIB, ramatercept |
Structure and chemistry
The construct takes the ligand binding ectodomain of ActRIIB, a compact three-finger toxin fold held by disulfides, and fuses it to an IgG1 Fc. The Fc contributes two things: it dimerises through the hinge disulfides, presenting two binding sites in the geometry the natural receptor uses on a membrane, and it engages the neonatal Fc receptor, which recycles the protein and extends serum persistence from hours to weeks.
Expression is in mammalian cells because the ectodomain disulfides and the conserved N-linked glycan on the Fc both require eukaryotic processing. Glycan heterogeneity is the main source of mass and charge variability in a preparation, and analytical characterisation covers the glycan profile, the fraction of correctly formed dimer, and any aggregate present. Size exclusion chromatography with multi-angle light scattering is the standard method for the last of those.
Fc fusion proteins are prone to two failure modes that a purity figure alone does not capture. Half-antibody species arise when hinge disulfides do not form, giving a monomer with one binding site and much weaker avidity. High molecular weight aggregates form under shear, at air interfaces and during freeze and thaw, and they behave differently from monomeric dimer in every assay. Reduced and non-reduced SDS-PAGE run alongside size exclusion chromatography is the minimum characterisation for material of this class.
Mechanism of action
Myostatin and activin A signal through type II receptors, ActRIIA and ActRIIB, which recruit ALK4 or ALK5 and phosphorylate SMAD2 and SMAD3. In skeletal muscle that pathway raises transcription of the atrogenes MuRF1 and atrogin-1 and restrains myoblast differentiation, so removing the ligands lifts a brake. ACE-031 intercepts the ligands in solution with high affinity, so no receptor complex assembles and SMAD2 and SMAD3 phosphorylation falls.
Specificity is the defining property and the main limitation. ActRIIB binds a broad set of TGF-beta family ligands, so a soluble ectodomain traps not only myostatin but activin A, activin B, GDF-11, BMP-9 and BMP-10. BMP-9 and BMP-10 govern vascular endothelial quiescence through ALK1, and their sequestration is the reason engineered variants with narrowed specificity became the focus of later work. Comparing ACE-031 against follistatin, anti-myostatin antibodies and specificity-tuned ActRIIB variants is a standard way to attribute an observed effect to a particular ligand.
Research applications
- Myoblast differentiation assays measuring fusion index and myosin heavy chain against myostatin challenge.
- SMAD2 and SMAD3 phosphorylation time courses quantifying ligand trap potency in muscle and endothelial lines.
- Surface plasmon resonance panels mapping affinity across myostatin, activin A, GDF-11, BMP-9 and BMP-10.
- Endothelial ALK1 signalling assays used to detect off-target sequestration of BMP-9 and BMP-10.
- Size exclusion chromatography and light scattering characterising dimer, half-antibody and aggregate content.
- Comparative ligand trap studies against follistatin and specificity-narrowed ActRIIB variants.
Compounds studied around muscle and connective tissue signalling sit in NuVion’s Tissue Repair Signalling category.
Handling in the laboratory
Fc fusion proteins are supplied lyophilised from a formulation buffer containing a sugar and a surfactant, and both are there for a reason. Reconstitution is with sterile or bacteriostatic water added slowly down the wall of the vial, then left to dissolve with gentle swirling. Vortexing or pipetting vigorously through an air interface generates aggregate in this class of protein faster than any other handling step. The reconstitution calculator converts vial content and diluent volume into a stock concentration.
Reconstituted material is aliquoted immediately and held frozen, because each freeze and thaw cycle adds aggregate that will not redissolve. Working dilutions in buffer without surfactant adsorb to plastic and glass, so a carrier protein is included where the assay permits. Where results drift between experiments, running size exclusion chromatography on the stock is more informative than repeating the assay, since aggregate content changes with handling history and is invisible in a concentration measurement.
Testing and supply from NuVion
NuVion supplies a tested range across tissue repair signalling, including BPC-157, TB-500, GHK-Cu and KPV, together with the KLOW blend. That range is manufactured at a GMP-audited facility and independently tested by Janoshik Analytical, with purity determined by RP-HPLC and identity confirmed by mass spectrometry, and the certificates are published in the Certificate of Analysis library. ACE-031 is not part of the current catalogue and this page is a reference profile.
Related compounds
The natural binding protein that traps the same ligand set is covered in follistatin. For growth factor signalling on the anabolic side, see IGF-1 LR3, MGF and HGH. Tissue repair endpoints in this library are covered by BPC-157, TB-500 and thymosin beta-4.
Frequently asked questions
How does ACE-031 differ from follistatin?
Both neutralise myostatin and activin, from opposite sides of the interaction. Follistatin is a natural binding protein that wraps around the ligand dimer. ACE-031 is an engineered decoy built from the receptor ectodomain, so its specificity is whatever ActRIIB itself binds. The two trap overlapping but not identical ligand sets, which is why they are often run side by side to attribute an effect.
Why does the Fc region matter?
It does two jobs. The hinge disulfides dimerise the construct so it presents two binding sites with the avidity a membrane receptor pair would have, and the Fc engages the neonatal Fc receptor, which recycles the protein out of the degradative pathway and extends serum persistence from hours to weeks.
What is the significance of BMP-9 and BMP-10 binding?
ActRIIB binds those two ligands in addition to myostatin and activin, and they maintain vascular endothelial quiescence through ALK1 signalling. Sequestering them produces effects unrelated to muscle, which is why later constructs were engineered to narrow specificity, and why endothelial assays are run alongside myoblast work on this molecule.
Is ACE-031 listed in the Australian Register of Therapeutic Goods?
No. ACE-031 is not included in the Australian Register of Therapeutic Goods and has not been assessed by the Therapeutic Goods Administration for quality, safety or efficacy. Recombinant material of this kind is supplied in Australia as a laboratory reagent for in vitro research.
Research use only. The compound described on this page is discussed as a laboratory chemical used in in vitro research. It is not included in the Australian Register of Therapeutic Goods and has not been assessed by the Therapeutic Goods Administration for quality, safety or efficacy. It is not for human or veterinary use, and nothing on this page is a representation about therapeutic use.
